Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 9;21(3):1144.
doi: 10.3390/ijms21031144.

Caspase-6 Knockout in the 5xFAD Model of Alzheimer's Disease Reveals Favorable Outcome on Memory and Neurological Hallmarks

Affiliations

Caspase-6 Knockout in the 5xFAD Model of Alzheimer's Disease Reveals Favorable Outcome on Memory and Neurological Hallmarks

Ariel Angel et al. Int J Mol Sci. .

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is the most common form of dementia in the elderly. Caspases, a family of cysteine proteases, are major mediators of apoptosis and inflammation. Caspase-6 is considered to be an up-stream modulator of AD pathogenesis as active caspase-6 is abundant in neuropil threads, neuritic plaques, and neurofibrillary tangles of AD brains. In order to further elucidate the role of caspase-6 activity in the pathogenesis of AD, we produced a double transgenic mouse model, combining the 5xFAD mouse model of AD with caspase-6 knock out (C6-KO) mice. Behavioral examinations of 5xFAD/C6-KO double transgenic mice showed improved performance in spatial learning, memory, and anxiety/risk assessment behavior, as compared to 5xFAD mice. Hippocampal mRNA expression analyses showed significantly reduced levels of inflammatory mediator TNF-α, while the anti-inflammatory cytokine IL-10 was increased in 5xFAD/C6-KO mice. A significant reduction in amyloid-β plaques could be observed and immunohistochemistry analyses showed reduced levels of activated microglia and astrocytes in 5xFAD/C6-KO, compared to 5xFAD mice. Together, these results indicate a substantial role for caspase-6 in the pathology of the 5xFAD model of AD and suggest further validation of caspase-6 as a potential therapeutic target for AD.

Keywords: Alzheimer’s disease; caspase-6; knock-out mice; neurodegeneration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Behavioral amelioration in 5xFAD/C6-KO female mice in the Y-maze and elevated plus maze.
Figure 2
Figure 2
Caspase-6 KO in 5xFAD mice improves cognitive performance in the Morris water maze test.
Figure 3
Figure 3
Caspase-6 KO in 5xFAD mice improves searching pattern in the probe test.
Figure 4
Figure 4
Synaptophysin is increased in 5xFAD/C6-KO double transgenic mice. Syn: Synaptophysin.
Figure 5
Figure 5
Altered gene expression in hippocampus of 5xFAD/C6-KO mice. Mice hippocampi were taken for RT-PCR analysis of several genes: mRNA quantification for female and male TNF-α (A,B), IL-10 (C,D); and Caspase-3 (Casp3; E,F) respectively. Data are mean ± SEM. *p < 0.05, **p < 0.01, and ****p < 0.0001. Two-tailed t-test between marked groups. NS: Not significant.
Figure 6
Figure 6
Caspase-6 KO in 5xFAD mice reduces amyloid-β plaque load. Representative images of hippocampal slices stained with ThioS for male (AB) and female (CD) transgenic mice and their respective quantification (n = 5–7). Scale bar = 200μm. Data are mean ± SEM. **p< 0.01 and ***p < 0.001. Two-tailed t-test.
Figure 7
Figure 7
Low IBA1 and GFAP expression in 5xFAD caspase-6 KO mice. Representative images of hippocampal slices stained with GFAP (AD) or IBA1 (EH). Quantification of GFAP and IBA1 are mean intensity of n = Scale bar = 25 μm. Data are mean ±SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Two-tailed t-test.

References

    1. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurol. 2013;80:1778–1783. doi: 10.1212/WNL.0b013e31828726f5. - DOI - PMC - PubMed
    1. Chen G.-F., Xu T.-H., Yan Y., Zhou Y.-R., Jiang Y., Melcher K., Xu H.E. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 2017;38:1205–1235. doi: 10.1038/aps.2017.28. - DOI - PMC - PubMed
    1. Murphy M.P., LeVine H. Alzheimer’s Disease and the β-Amyloid Peptide. J. Alzheimers Dis. 2010;19:331. doi: 10.3233/JAD-2010-1221. - DOI - PMC - PubMed
    1. Lu D.C., Rabizadeh S., Chandra S., Shayya R.F., Ellerby L.M., Ye X., Salvesen G.S., Koo E.H., Bredesen D.E. A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor. Nat. Med. 2000;6:397–404. doi: 10.1038/74656. - DOI - PubMed
    1. Sakamaki K., Satou Y. Caspases: evolutionary aspects of their functions in vertebrates. J. Fish Boil. 2009;74:727–753. doi: 10.1111/j.1095-8649.2009.02184.x. - DOI - PMC - PubMed

LinkOut - more resources